Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $11.00 (143.36% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/8/2013Brean CapitalBoost Price Target$14.00 -> $16.00ViewTweet This Rating  Share This Rating on StockTwits
8/9/2013Bank of AmericaDowngradeBuy -> Neutral$13.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
8/9/2013OppenheimerLower Price TargetOutperform$12.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
8/8/2013Cowen and CompanyDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
7/22/2013UBS AGInitiated CoveragePositiveViewTweet This Rating  Share This Rating on StockTwits
6/24/2013MizuhoInitiated CoverageBuy$12.00ViewTweet This Rating  Share This Rating on StockTwits
11/9/2012GuggenheimInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
9/27/2012Brean CapitalInitiated CoverageBuy$12.00ViewTweet This Rating  Share This Rating on StockTwits
8/31/2012Bank of AmericaInitiated CoverageBuy$13.00ViewTweet This Rating  Share This Rating on StockTwits
5/8/2012Cowen and CompanyInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
5/8/2012OppenheimerInitiated CoverageOutperform$12.00ViewTweet This Rating  Share This Rating on StockTwits
5/8/2012JPMorgan Chase & Co.Initiated CoverageOverweight$10.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 4/19/2012 forward)